Background: Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival).
Introduction
Primary carcinoma of the lung is one of the most mutated of solid tumors [1] , reflecting the importance of tobacco carcinogenesis in the development of most cases, and contributing to the generally aggressive clinical course of these tumors. Recently, there has been focus on identifying molecular drivers in advanced stage nonsmall-cell lung carcinomas (NSCLC), primarily adenocarcinomas. Driver tyrosine kinases may be therapeutically targeted, an approach which is, in general, beneficial to patients [2] . An expanding list of probable molecular drivers and corresponding inhibitory drugs has driven interest in multiplex genomic testing in NSCLC, as a means of efficiently detecting possible targets in individual cases. Assessment of therapy outcomes may be confounded by any prognostic effect that any such molecular drivers may confer.
The prognostic effect of EGFR mutation in resected disease is still disputed [3] . Our previous work in Lungscape showed a prognostic significance of ALK gene rearrangements [4] but for many other emerging molecular drivers the effect is unclear [5] . Such data will become more relevant as disease staging systems become more sophisticated and provide better prognostication beyond tumor stage; a molecular staging system to compliment TNM is becoming a real prospect.
Datasets describing mutations in large surgically resected lung tumor cohorts, in association with clinical data, are relatively few, mainly adenocarcinomas, and mostly derived from North American or East Asian centers [6] [7] [8] [9] . The European Thoracic Oncology Platform (ETOP) Lungscape database (iBiobank) is a virtual biobank of fully clinically annotated, surgically resected NSCLCs [10] . In this study, mutation profiles derived from a multigene, multiplex platform were generated, and compared with clinicopathologic characteristics and post-operative patient outcomes.
Materials and methods
The ETOP Lungscape iBiobank holds extensive clinicopathologic data on over 2700 resected stage I-III NSCLCs, with 3 years follow-up.
The research was conducted according to Lungscape master and MULTIPLEX sub-study protocols; with adherence to country specific ethics, regulatory requirements and REMARK recommendations.
For each case, a paraffin block containing 30% tumor was cut, using measures to avoid cross-case contamination, and resulting 4-5 lm thick paraffin sections were used for DNA extraction from tumor rich regions (usually >50%) using the QIAamp DNA FFPE Tissue kit (Qiagen, Hilden, FRG). Extracted DNA samples were analysed for quality by Spectrophotometric analysis and shipped to Laboratory of Oncology, Quiron Dexeus University Hospital, Barcelona. All samples had ratios A260/A280 in the interval 1.8 6 0.1 and standard UV spectra (220-320 nm). Samples were anonymized, diluted to 50 ng/ml and a minimum of 30 ml (corresponding to 1500 ng) was shipped to Genentech Inc., South San Francisco for mutation testing.
Testing was carried out on a high-throughput microfluidics-based PCR platform running an allele-specific multiplex test (further details in Supplementary Data, available at Annals of Oncology online). A previously described validated panel was updated to include 13 genes (AKT1, BRAF, EGFR, ERBB2, FLT3, HRAS, JAK2, KIT, KRAS, MET, MYD88, NRAS and PIK3CA) incorporating 130 hot-spot mutations found in various tumor types [11] [12] [13] (supplementary Table S1 , available at Annals of Oncology online). The mutant-allele detection sensitivity is >1% with a minimum requirement of 2-100 ng DNA.
Clinicopathologic characteristics were compared between groups of patients, by mutation status or histology type, using Fisher's exact, Mantel-Haenszel or Mann-Whitney test.
Cases with mutation detected (MD) or mutation not detected (MND) were considered in prevalence estimation and 95% exact binomial confidence interval (95% CI), for each available gene. Further analyses were limited to genes with a sufficient number of detected mutations.
Correlation of mutations with MET (clone SP44) and ALK (clone 5A4) expression, available from previous Lungscape studies [4, 5, 14] , was evaluated through Fisher's exact tests.
Clinical outcome is presented by overall survival (OS, time from surgery date to death from any cause); relapse-free survival (RFS, time from surgery date to first relapse or death from any cause) and time-to-relapse (TTR, time from surgery date to first relapse) [4, 10] . Median follow-up time was estimated using the reverse censoring method for OS.
The effect of gene mutations on outcome was explored through Cox proportional hazards regression models, adjusted for a series of clinicopathologic characteristics: gender, ethnicity, smoking history, age, adjuvant chemotherapy, adjuvant radiotherapy, previous history of cancer, performance status at diagnosis, stage, primary tumor localization, tumor size, histology, surgery year, technique and anatomy. Backwards elimination method (removal P 0.10) was used to identify the final models with significant outcome prognostic factors. Hazard ratios (HRs), along with 95% CIs, were estimated and differences in hazard were depicted graphically via Kaplan-Meier curves.
In all exploratory analyses, results with two-sided P-value 0.05 were considered significant. Analyses were carried out overall and separately for the two primary histology groups: adenocarcinomas and squamous cell carcinomas (SCCs).
Statistical analyses were carried out in SAS 9.3 and R 3.2.2.
Results

Description of multiplex cohort
Current analysis was based on 2063 cases from 16 centers (multiplex cohort), 76.2% of the overall Lungscape population [10] , consisting of 1017 adenocarcinomas (49.3%), 888 SCCs (43.0%) and 158 (7.7%) undifferentiated or adenosquamous/combinedmixed carcinomas. Clinicopathologic characteristics, overall, and for the two primary histology groups are presented in Table 1 , where some significant differences between the histology groups were detected.
Prevalence of gene mutations
Overall, KRAS mutations were the most frequently encountered (23.0%; 95% CI: 21.2-24.9), followed by mutations in MET (6.8%; 95% CI: 5.8-8.0), EGFR (5.4%; 95% CI: 4.5-6.5) and PIK3CA (4.9%; 95% CI: 4.0-6.0). Only 0.7% of cases showed BRAF mutations whilst mutations in NRAS, HRAS, MYD88, AKT1 and KIT were very uncommon. There were no mutations found in ERBB2, FLT3 and JAK2 (Table 2 ).
In the adenocarcinomas, KRAS mutations remained dominant (38.0%; 95% CI: 35.0-41.0), while EGFR mutations were the second most frequent (9.7%; 95% CI: 7.9-11.7). Both KRAS and EGFR mutations were significantly more frequent in adenocarcinomas compared with SCCs (both P < 0.001; Table 2 ).
PIK3CA mutation was reported in 7.1% of SCCs (95% CI: 5.5-9.1) and was significantly more frequent compared with adenocarcinomas (P < 0.001; Table 2 ).
Supplementary Table S2 , available at Annals of Oncology online, presents the mutations reported for the most frequent genes, overall and for adenocarcinomas/SCCs.
Co-existence of mutations and associations with MET and ALK IHC expression
Co-existence of KRAS and either EGFR or PIK3CA mutations were exceptionally rare (supplementary Figure S1A -C, available at Annals of Oncology online). Only two adenocarcinomas showed dual KRAS/EGFR mutation (Eg_19del/Kr_G12S; Eg_S768I/Kr_G12V), and nine cases dual KRAS/PIK3CA mutation (seven adenocarcinomas, two large cell carcinomas). There were three adenocarcinomas and one SCC with EGFR/PIK3CA mutation co-existence.
There was one adenocarcinoma with dual EGFR mutation (G719X/S768I), and one SCC with two PIK3CA mutations (H1047R/E545K).
KRAS and EGFR mutations were significantly more frequent in the MET IHC positive group (KRAS: 34.2% in MET IHC positive versus 19.8% in negative, P < 0.001; EGFR: 10.4% in positive versus 4.0% in negative: P < 0.001). There was no difference in MET IHC status by PIK3CA or MET gene mutations (supplementary Table S3 , available at Annals of Oncology online).
For adenocarcinomas, only the association of MET IHC overexpression with EGFR mutation remains significant (P ¼ 0.0014), while for SCC, only the association with KRAS mutation (P < 0.001) (supplementary Table S3 , available at Annals of Oncology online).
There was no significant association between ALK IHC expression, evaluated in adenocarcinomas, and KRAS, MET, EGFR or PIK3CA mutations (supplementary Table S4 , available at Annals of Oncology online).
Associations between mutations and smoking status
A significant association was detected between KRAS and EGFR genes and smoking status overall (P ¼ 0.0065 and P < 0.001), and for adenocarcinomas (both P < 0.001), but not for SCCs (P > 0.99 and P ¼ 0.37) ( (Table 3) . KRAS mutation type by smoking status is presented in supplementary Table S5 , available at Annals of Oncology online. Regarding MET and PIK3CA mutations, a significant association was observed only between MET mutation status and smoking history (P ¼ 0.032) in SCCs, with MET mutations more frequently observed in never smokers (15.0%; 95% CI: 7.1-26.6) ( Table 3) .
Time-to-event outcome and mutation status RFS, TTR and OS were evaluated at a median follow-up of 4.75 years. An RFS event was experienced by 51.6% of patients, with 5-year RFS 47.3% (95% CI 44.9-49.6). TTR events were experienced by 40.0% of patients, with 5-year TTR 56.6% (95% CI: 54.2-59.0). The total number of deaths recorded was 925 (44.8%), with 5-year OS 53.7% (95% CI: 51.3-56.1). Median OS was 72.0 months, and no difference was detected by mutation status for any gene (all P-values non-significant, un-stratified or stratified by histology or stage); this also holds for RFS and TTR. No effect of gene mutation and adjuvant therapy on outcome was detected (their effect on all Cox models was non-significant; sup plementary Tables S6-S8, available at Annals of Oncology online).
Analysing patient outcome by the three codon groups of KRAS mutations (12/13/61/MND), in the corresponding adjusted models, a significant effect of codon 61 mutation is observed for TTR, but not for RFS (marginally) and OS (P ¼ 0.039, P ¼ 0.057 and P ¼ 0.16, respectively; supplementary Table S9, available 
Discussion
This is one of the largest cohorts of surgically resected European NSCLC patients exploring associations of driver mutations with clinicopathologic features. The patient demographics are in line with what would be expected for such a cohort in terms of stage distribution and post-operative outcomes [10] . The histologic distribution is slightly biased against undifferentiated tumors, comprising 4.7% of the cohort versus an expected prevalence of around 12% in an unselected cohort using WHO 2004 criteria. A 43% prevalence of SCC is representative for a European patient The microfluidics-based PCR platform used for mutation testing was originally developed for testing multiple tumor types, with a corresponding range of clinically relevant genes and mutations. Test sensitivity and sample requirements were within parameters met by the material used in this study. This platform provides an allele-specific range of mutations to be tested but is limited in terms of more recent developments in mutations of interest. The range of BRAF mutations, for example, was limited to V600E and V600K. The MET mutations found are polymorphisms of questionable clinical significance [15] [16] [17] ; MET exon14 skipping mutations were not tested [5, 18, 19] , which is a limitation of our study.
The mutations found and their relation to tumor histology and smoking status are again, largely in line with previous reports [6] [7] [8] [9] , bearing in mind that the allele-specific technique used in this study risks under-estimating gene mutation prevalence compared with studies where whole exons are sequenced. KRAS and EGFR would be the expected dominant findings in adenocarcinomas, as would PIK3CA in SCCs. The prevalence of KRAS mutation subtype is in line with expectations [6, 9] , predominantly represented by G12C change (G12D commonest in never smokers). European cohorts have also previously shown a dominance of exon 19 EGFR deletions over L858R substitution mutations [20] . BRAF mutations, all V600E, were found in only 1.1% of our adenocarcinomas. Marchetti et al. [21] reported a 4.7% prevalence in 739 resected adenocarcinomas after screening BRAF exons 11 and 15, but only 2.8% for V600E mutations. Marchetti et al. [21] and the current study found a very low prevalence of BRAF mutation in SCC. The rare EGFR mutations found in SCC in this study were largely confined to never or former smokers, a trait reflected in testing recommendations [22, 23] . Similarly, KRAS mutations that were smoking-associated in adenocarcinomas, showed no such correlation in SCC. The association between MET IHC expression and EGFR mutation in adenocarcinoma, and KRAS mutation in SCC, has not been previously reported; the biologic significance of this is unclear. Only rare coexistence of KRAS and EGFR mutations is as expected; equally, PIK3CA mutations are known to co-exist with KRAS or EGFR mutations [24] , albeit this is not frequently observed.
The lack of any association between KRAS, EGFR or PIK3CA mutation and post-operative outcome is, perhaps, surprising. KRAS mutations have previously been shown to be associated with poor post-operative survival [25] [26] [27] , but more recently, this has been challenged [28] [29] [30] . Shepherd et al. reported a deleterious effect of codon 13 KRAS mutations in patients receiving adjuvant chemotherapy [28] . This KRAS mutation subgroup did not have an inferior post-operative survival in the absence of adjuvant therapy. Our finding of better outcomes in rare codon 61 mutations is of uncertain significance. Most studies have suggested that EGFR mutations are associated with a good prognosis although again, this is not a universal finding [3, 27, 29, 31] . The observed prevalence of PIK3CA mutations of 4.9% overall, higher in SCC (7.1%) and lower in adenocarcinomas (3.3%) is in line with previous report [24] , which also included stage IV patients but, like us, described no prognostic significance for PIK3CA mutation.
The data in our study derive from one of the largest, wellannotated database, focusing on early NSCLC. This series suggests that at least the three most frequently found mutations (KRAS, EGFR and PIK3CA) would have little role in a molecular staging system. We do note, however, that the prevalence of EGFR and PIK3CA gene mutations is low, though not unusually so, such that prognostication is based on relatively few patients. This illustrates the challenges of studying single genes as prognostic indicators, even in large studies such as this. Mutations of even lower prevalence would have no value in this regard, unless of very strong prognostic significance; mutations of high prevalence, such as TP53 (not available in this study), may be a more likely candidate. It is more likely that, should there be a relevant mutational profile related to prognosis, it would involve several genes. This is akin to the plethora of historical data on gene expression profiles relating to prognosis in resected NSCLC [32] [33] [34] [35] [36] . This study found relatively few cases with co-existent mutations but this is a reflection of the panel of genes examined, focusing on possible drug targets. Wider genome profiling will have a greater chance of identifying prognostically significant panel of genes or gene signatures. These findings also emphasize the potential benefits of merging large databases, to identify and describe rare, but potentially clinically useful, mutation profiles.
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